Company Announcements

CHICAGO--(BUSINESS WIRE)--Apr. 23, 2026-- Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell in response to the Department of Justice’s final rule publication rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act.

“Rescheduling medical cannabis is a long-overdue step that finally brings federal policy closer to the science. For the first time in history, our federal government is classifying cannabis as medicine, validating the experiences of millions of patients who rely on it to help manage serious conditions and live better lives.

This decision opens the door to expanded research, better data, more informed care, and broader access for those who need it most. It is a win for all patients nationwide and will usher in a new era of healthcare, where cannabis is treated like any other medicine. Cresco Labs commends President Trump and the administration for following through on bringing a commonsense approach to cannabis regulation.”

About Cresco Labs Inc.

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423797861/en/

Media
press@crescolabs.com

Investors
Sharon Schuler, Chief Financial Officer
investors@crescolabs.com

General Inquiries
312-929-0993
info@crescolabs.com

Source: Cresco Labs